Phase 3 randomized trial evaluating second-line hormonal therapy versus docetaxel-estramustine combination chemotherapy on progression-free survival in asymptomatic patients with a rising prostate-specific antigen level after hormonal therapy for prostate cancer: an Eastern Cooperative Oncology Group (E1899), intergroup/clinical trials support unit study

✍ Scribed by Janet R Walczak; Michael A Carducci

• Book ID: 116943865
• Publisher: Elsevier Science
• Year: 2003
• Tongue: English
• Weight: 113 KB
• Volume: 62
• Category: Article
• ISSN: 0090-4295
• DOI: 10.1016/j.urology.2003.09.006